Physician profile
David Vroman
NPI 1750393138
$60,896.03
in general payments reported to CMS, 2019-2025
36 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,005 · 2020: $722 · 2021: $1,048 · 2022: $1,757 · 2023: $1,482 · 2024: $26K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Food and Beverage: $9,956 · Long Term Medical Supply Or Device Loan: $7,475 · Travel and Lodging: $4,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,187.50 |
| Food and Beverage | $9,956.02 |
| Long Term Medical Supply Or Device Loan | $7,474.85 |
| Travel and Lodging | $4,746.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $25,417.72 | 2024-2025 | Air Optix, Unity |
| Glaukos Corporation | $20,959.30 | 2020-2025 | Epioxa, Travoprost Intraocular Implant - Idose, Ce-Marked Kxla System |
| Alcon Vision LLC | $3,275.44 | 2019-2025 | Clareon, Rocklatan, Argos |
| Biotissue Holdings INC. | $2,263.66 | 2019-2025 | |
| Dompe US, INC. | $1,363.60 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $976.68 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Harrow Eye, LLC | $768.05 | 2024-2025 | Vevye, Iheezo |
| Ocular Therapeutix, INC. | $743.63 | 2019-2025 | Dextenza |
| Abbvie INC. | $689.24 | 2022-2025 | Xen Glaucoma Treatment System, Vuity, Alphagan P |
| Sun Pharmaceutical Industries INC. | $644.92 | 2019-2025 | Cequa |
| Rxsight INC | $553.68 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Novartis Pharmaceuticals Corporation | $405.61 | 2019-2023 | |
| Oyster Point Pharma, INC. | $334.61 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $290.87 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $259.65 | 2019-2024 | Tecnis Iol |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $236.00 | 2019-2022 | |
| Omeros Corporation | $189.43 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $174.85 | 2023-2025 | Omidria, Rayone Emv, Rayone Spheric |
| New World Medical,INC. | $173.08 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $139.06 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $134.15 | 2024-2025 | Xdemvy |
| Allergan, INC. | $127.84 | 2019-2022 | |
| Avedro INC. | $126.30 | 2019 | |
| Sight Sciences, INC. | $123.39 | 2024 | Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $106.56 | 2019-2021 | |
| Shire North American Group INC | $106.26 | 2019 | |
| Staar Surgical Company | $95.21 | 2019 | |
| Horizon Therapeutics Plc | $56.21 | 2022-2023 | Tepezza |
| Carl Zeiss Meditec, INC. | $36.11 | 2024 | |
| Eyevance Pharmaceuticals LLC | $24.79 | 2019 | |
| Akorn, INC. | $22.62 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ivantis, INC | $16.27 | 2020 | |
| Amgen INC. | $14.86 | 2025 | Tepezza |
| Spinal Simplicity, LLC | $13.53 | 2023 | Ha Minuteman G3-R |
| Merz Pharmaceuticals, LLC | $13.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vroman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.